Protein expression company focused on development of biosimilar drugs
Location: United States, California, San Diego
Investors 1
| Date | Name | Website |
| - | Signet Hea... | signetheal... |
Mentions in press and media 4
| Date | Title | Description |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 21.08.2015 | Morning Read: Novartis buys up rights to GSK’s MS drug for up to $1B, anthrax vaccine developer Pfenex wins $143.5M contract | Pfenex Inc. a California biotech working on an anthrax vaccine to compete against Emergent BioSolutions Inc.’s BioThrax, is receiving a federal contract worth up to $143.5 million, it was announced this week. — Washington Business Journal L... |
| 08.06.2014 | Pfenex Inc. Aims for $74.8M IPO | Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars. The company, which employs 25 and was founded in 2009... |
| - | Morning Read: Novartis buys up rights to GSK’s MS drug for up to $1B, anthrax vaccine developer Pfenex wins $143.5M contract | TOP STORIES Novartis has acquired the remaining rights to GlaxoSmithKline’s multiple sclerosis drug Ofatumumab for up to $1 billion. It is developing the drug for relapsing remitting multiple sclerosis and other auto-immune conditions. — Re... |